+86(1812)4514114 info@phcoker.com

Raw Octreotide Acetate powder (79517-01-4)

Raw Octreotide Acetate powder is a potent, long-acting synthetic SOMATOSTATIN octapeptide analog that………


Status: In Mass Production
Synthesized and Customized Available
Capacity: 1277kg/month

Description

Raw Octreotide Acetate powder (79517-01-4) video

 

Raw Octreotide Acetate powder (79517-01-4) Description

Raw Octreotide Acetate powder is a potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.

Raw Octreotide Acetate powder is the acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.

Raw Octreotide Acetate powder (79517-01-4) Specifications

Product Name Raw Octreotide Acetate powder
Chemical Name Octreolin; Sandostatin LAR; SMS 201-995 AC; Longastatina

acetic acid

Brand Name Sandostatin
Drug Class Peptide
CAS Number 79517-01-4
InChIKey XQEJFZYLWPSJOV-XJQYZYIXSA-N
Molecular Formula C51H70N10O12S2
Molecular Weight 1079.299 g/mol
Monoisotopic Mass 1078.462 g/mol
Melting Point  >140°C (dec.)
Freezing Point N/A
Biological Half-Life 100 minutes
Color White to Off-White
Solubility  Acetic Acid (Slightly), DMSO (Slightly), Methanol (Slightly)
Storage Temperature  -20°C Freezer
Application Octapeptide analog of Somatostatin. A gastric antisecretory agent. Used in treatment of acromegaly.

 


=

References & product citations

Octreotide Acetate Injection: Are you ready to use it?

 

References

Shima, Y., Sasaki, Y., Shirao, K., and Ohtsu, A. (2008). Clinical Efficacy and Safety of Octreotide in Terminally Ill Japanese Cancer Patients with Malignant Bowel Obstruction. Clinical Oncology.

Lamberts, S.W., Van der Lely, A.J, and De Herder, W.W. (1997). A Risk-Benefit Assessment of Octreotide in the Treatment of Acromegaly.

Gotzsche, P.C., and Hrobjartsson, A. (2008). Somatostatin Analogues for Acute Bleeding Esophageal Varices.

Lustig, R.H., Xiong, X., Hinds, P.S., et al. (2003). Octreotide Therapy of Pediatric Hypothalamic Obesity.

Chadha, K.M., Lombardo, J., Mashtare, T., et al. (2009). High Dose Octreotide Acetate for Management of Gastroenteropancreatic Neuroendocrine Tumors. International Journal of Cancer Research and Treatment.

Chaudhry, R., Singh, B., and Subhas, P. (2017). Octreotide in Gastroenterology. Medical Journal, Armed Forces India.

Sharkey, A.J., and Rap, N.J. (2012). The Successful Use of Octreotide in the Treatment of Traumatic Chylothorax. Texas Heart Institute Journal.